-+ 0.00%
-+ 0.00%
-+ 0.00%

ARVINAS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 CLINICAL TRIAL OF ARV-6723, THE COMPANY’S FIRST IMMUNO-ONCOLOGY CANDIDATE

Reuters·09/28/2026 11:00:00

Please log in to view news